Silexion Therapeutics Corp — Form 8-K
Filed August 21, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Silexion Therapeutics Corp filed an 8-K on 2026-08-21 reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing provides no specific dollar amounts, share counts, or detailed remediation plans. The company (total assets ~$4.6M, Israel-based biotech) has triggered an exchange delisting notice, indicating it has failed to meet continued listing standards, though the exact non-compliance reason is not disclosed in this extract.
Why this rating
Delisting is business-critical for any public company; represents loss of exchange access, liquidity, and credibility. Extreme relative to $4.6M asset base.
Extracted items
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.